These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38991462)

  • 1. Bacterial glycoengineering: Cell-based and cell-free routes for producing biopharmaceuticals with customized glycosylation.
    Palma JA; Bunyatov MI; Hulbert SW; Jewett MC; DeLisa MP
    Curr Opin Chem Biol; 2024 Aug; 81():102500. PubMed ID: 38991462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Customized protein glycosylation to improve biopharmaceutical function and targeting.
    Van Landuyt L; Lonigro C; Meuris L; Callewaert N
    Curr Opin Biotechnol; 2019 Dec; 60():17-28. PubMed ID: 30554064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-Free Systems for the Production of Glycoproteins.
    Bidstrup EJ; Kwon YH; Kim K; Bandi CK; Aw R; Jewett MC; DeLisa MP
    Methods Mol Biol; 2024; 2762():309-328. PubMed ID: 38315374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoengineering of Antibodies for Modulating Functions.
    Wang LX; Tong X; Li C; Giddens JP; Li T
    Annu Rev Biochem; 2019 Jun; 88():433-459. PubMed ID: 30917003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging technologies for making glycan-defined glycoproteins.
    Wang LX; Lomino JV
    ACS Chem Biol; 2012 Jan; 7(1):110-22. PubMed ID: 22141574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plant glycoengineering for designing next-generation vaccines and therapeutic proteins.
    Strasser R
    Biotechnol Adv; 2023 Oct; 67():108197. PubMed ID: 37315875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hijacking bacterial glycosylation for the production of glycoconjugates, from vaccines to humanised glycoproteins.
    Cuccui J; Wren B
    J Pharm Pharmacol; 2015 Mar; 67(3):338-50. PubMed ID: 25244672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacterial Glycoengineering as a Biosynthetic Route to Customized Glycomolecules.
    Yates LE; Mills DC; DeLisa MP
    Adv Biochem Eng Biotechnol; 2021; 175():167-200. PubMed ID: 30099598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoenzymatic Glycan Remodeling of Natural and Recombinant Glycoproteins.
    Yang Q; Wang LX
    Methods Enzymol; 2017; 597():265-281. PubMed ID: 28935106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of fully functional proteins with novel glycosylation via enzymatic glycan trimming.
    Toumi ML; Go EP; Desaire H
    J Pharm Sci; 2009 Aug; 98(8):2581-91. PubMed ID: 19117044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-glycosylation engineering of biopharmaceutical expression systems.
    Jacobs PP; Callewaert N
    Curr Mol Med; 2009 Sep; 9(7):774-800. PubMed ID: 19860659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using glyco-engineering to produce therapeutic proteins.
    Dicker M; Strasser R
    Expert Opin Biol Ther; 2015; 15(10):1501-16. PubMed ID: 26175280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cell-free biosynthesis platform for modular construction of protein glycosylation pathways.
    Kightlinger W; Duncker KE; Ramesh A; Thames AH; Natarajan A; Stark JC; Yang A; Lin L; Mrksich M; DeLisa MP; Jewett MC
    Nat Commun; 2019 Nov; 10(1):5404. PubMed ID: 31776339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shotgun scanning glycomutagenesis: A simple and efficient strategy for constructing and characterizing neoglycoproteins.
    Li M; Zheng X; Shanker S; Jaroentomeechai T; Moeller TD; Hulbert SW; Koçer I; Byrne J; Cox EC; Fu Q; Zhang S; Labonte JW; Gray JJ; DeLisa MP
    Proc Natl Acad Sci U S A; 2021 Sep; 118(39):. PubMed ID: 34551980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of therapeutic glycoproteins in glycoengineered plant: old farm for new crops.
    Kao MR; Karmarkar Saldivar R; Hsieh YSY
    Curr Opin Biotechnol; 2024 Jun; 87():103145. PubMed ID: 38781701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacterial glycobiotechnology: A biosynthetic route for the production of biopharmaceutical glycans.
    Paliya BS; Sharma VK; Tuohy MG; Singh HB; Koffas M; Benhida R; Tiwari BK; Kalaskar DM; Singh BN; Gupta VK
    Biotechnol Adv; 2023 Oct; 67():108180. PubMed ID: 37236328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Off-target glycans encountered along the synthetic biology route toward humanized N-glycans in Pichia pastoris.
    Laukens B; Jacobs PP; Geysens K; Martins J; De Wachter C; Ameloot P; Morelle W; Haustraete J; Renauld JC; Samyn B; Contreras R; Devos S; Callewaert N
    Biotechnol Bioeng; 2020 Aug; 117(8):2479-2488. PubMed ID: 32374435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic glycoengineering in mammalian cells.
    Narimatsu Y; Büll C; Chen YH; Wandall HH; Yang Z; Clausen H
    J Biol Chem; 2021; 296():100448. PubMed ID: 33617880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycan Remodeling of Human Erythropoietin (EPO) Through Combined Mammalian Cell Engineering and Chemoenzymatic Transglycosylation.
    Yang Q; An Y; Zhu S; Zhang R; Loke CM; Cipollo JF; Wang LX
    ACS Chem Biol; 2017 Jun; 12(6):1665-1673. PubMed ID: 28452462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of glycosylation on viral vaccines.
    Lembo A; Molinaro A; De Castro C; Berti F; Biagini M
    Carbohydr Polym; 2024 Oct; 342():122402. PubMed ID: 39048237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.